Q-omics provides the consensus-scored DHX33-DT profile across patient tissues and cancer cell-line models. DHX33-DT expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, DHX33-DT is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, DHX33-DT RNA expression shows 5,889 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight OV, UCEC, and STAD as cancer lineages where DHX33-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHX33-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHX33-DT survival associations across molecular data types. DHX33-DT RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHX33-DT RNA expression–survival associations across cancer types. High DHX33-DT expression shows unfavorable associations in LGG, DLBC and LUSC, but favorable associations in OV, PAAD and HNSC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for DHX33-DT RNA expression.
This table summarizes DHX33-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DHX33-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHX33-DT shows lower tumor expression in KIRC and higher tumor expression in UCEC. The UCEC box plot shows higher DHX33-DT RNA expression in tumor versus normal tissue (log2 FC = +0.155, t-test p = .034).
This table shows molecular features associated with DHX33-DT in patient tissues and cancer cell lines. In patient samples, DHX33-DT shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
